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Quantitative measures of estrogen receptor
expression in relation to breast cancer-specific
mortality risk among white women and black
women
Huiyan Ma1*, Yani Lu1, Polly A Marchbanks2, Suzanne G Folger2, Brian L Strom3, Jill A McDonald2,
Michael S Simon4, Linda K Weiss5, Kathleen E Malone6, Ronald T Burkman7, Jane Sullivan-Halley1,
Dennis M Deapen8, Michael F Press9 and Leslie Bernstein1

Abstract
Introduction: The association of breast cancer patients’ mortality with estrogen receptor (ER) status (ER + versus ER-)
has been well studied. However, little attention has been paid to the relationship between the quantitative measures
of ER expression and mortality.
Methods: We evaluated the association between semi-quantitative, immunohistochemical staining of ER in formalinfixed paraffin-embedded breast carcinomas and breast cancer-specific mortality risk in an observational cohort of
invasive breast cancer in 681 white women and 523 black women ages 35-64 years at first diagnosis of invasive breast
cancer, who were followed for a median of 10 years. The quantitative measures of ER examined here included the
percentage of tumor cell nuclei positively stained for ER, ER Histo (H)-score, and a score based on an adaptation of an
equation presented by Cuzick and colleagues, which combines weighted values of ER H-score, percentage of tumor
cell nuclei positively stained for the progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)
results. This is referred to as the ER/PR/HER2 score.
Results: After controlling for age at diagnosis, race, study site, tumor stage, and histologic grade in multivariable Cox
proportional hazards regression models, both percentage of tumor cell nuclei positively stained for ER (Ptrend = 0.0003)
and the ER H-score (Ptrend = 0.0004) were inversely associated with breast cancer-specific mortality risk. The ER/PR/HER2
score was positively associated with breast cancer-specific mortality risk in women with ER + tumor (Ptrend = 0.001).
Analyses by race revealed that ER positivity was associated with reduced risk of breast cancer-specific mortality in white
women and black women. The two quantitative measures for ER alone provided additional discrimination in breast
cancer-specific mortality risk only among white women with ER + tumors (both Ptrend ≤ 0.01) while the ER/PR/HER2
score provided additional discrimination for both white women (Ptrend = 0.01) and black women (Ptrend = 0.03) with
ER + tumors.
Conclusions: Our data support quantitative immunohistochemical measures of ER, especially the ER/PR/HER2
score, as a more precise predictor for breast cancer-specific mortality risk than a simple determination of ER
positivity.
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Introduction
The estrogen receptor (ER), which was identified in the
late 1960s, is a protein molecule located in the nuclei of
hormone target cells [1]. ER contains a specific ligand
binding domain to which only estrogen or closely related
molecules can bind. The positivity of ER in breast cancer
tissue was first considered a strong indicator of response
to endocrine therapy in the early 1970s [2] and was first
recognized as a prognostic factor in the late 1970s [3].
Historically, ER expression in breast tissue was quantified using ligand binding assays, such as the most commonly used dextran-coated charcoal (DCC) assay [4,5].
Ligand binding assays quantify the amount of ERs with
unoccupied ligand binding domains (those that have not
bound estrogen or a closely related molecule) by measuring the amount of radiolabeled specific binding of estradiol in tissue homogenates [6]. Since the development
of monoclonal antibodies to ER in the 1980s, ligand
binding assays have been gradually replaced by monoclonal
assays that measure both unoccupied and occupied ERs
[7,8]. There are two types of monoclonal assays: the quantitative enzyme immunoassay [7] and the semi-quantitative
immunohistochemistry (IHC) assay [8,9].
The ease of performing an IHC assay on routinely prepared formalin-fixed paraffin-embedded tissue blocks,
combined with the assay’s ability to evaluate small
tumor samples and to ensure that only tumor cells are
assessed, has led to the IHC assay becoming the first
choice for ER measurement in pathology. The lack of a
standardized cutoff point for ER positivity has been a
longstanding issue. However, in 2010 the joint panel of
the American Society of Clinical Oncology and the
College of American Pathologists published guidelines
recommending that ≥1% of tumor nuclei positively
stained for ER should be the cutoff point for ER positivity [10]. The panel also noted that few follow-up studies
had been published assessing quantitative staining of ER
in tissue as a prognostic indicator. In 2011 Cuzick and
colleagues reported that, in the Arimidex, Tamoxifen,
Alone or in Combination trial, the quantitative ER Histo
(H)-score alone or in combination with three other
markers (progesterone receptor (PR), human epidermal
growth factor receptor 2 (HER2) and Ki-67) was associated with risk of distant recurrence in postmenopausal
women who were diagnosed with ER-positive breast
cancer [11].
Here we present results from an observational cohort
study of white women and black women with invasive
breast cancer in which two quantitative measures of ER
alone and an adaptation of Cuzick’s combined score,
based on quantitative values of ER and PR, and HER2
status [11], were assessed to determine how they compare with each other and with ER status (positive versus
negative) in predicting mortality risk.
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Methods
Study population and data collection

The participants were breast cancer patients from Detroit
and Los Angeles (LA) who participated in the Women’s
Contraceptive and Reproductive Experiences (CARE)
Study, a population-based, case–control study designed to
examine risk factors for invasive breast cancer among
white women and black women [12]. The Women’s CARE
Study selected a stratified (by age group) random sample
of women ages 35 to 64 years who were newly diagnosed
with histologically confirmed, first primary invasive breast
cancer (International Classification of Diseases for Oncology codes C50.0 to C50.9) between July 1994 and April
1998. Black women were oversampled to maximize their
numbers in the study, and white women were sampled to
provide approximately equal numbers of women in each
5-year age group between 35 and 64 years. The Women’s
CARE Study recruited and interviewed 1,921 breast cancer patients from Detroit (n = 679) and LA (n = 1,242).
These two study sites were selected to collect tumor tissue
samples based on representative case participants in the
Women’s CARE Study and the ability to obtain tumor
tissue samples. All participants provided written informed consent. The study protocol was approved by
the Institutional Review Boards at the University of
Southern California, the Karmanos Comprehensive
Cancer Center, the Centers for Disease Control and Prevention, and the City of Hope.
Assessment of biomarkers

Formalin-fixed paraffin-embedded tumor blocks were
successfully retrieved from pathology laboratories where
diagnoses were made for 1,333 participating breast cancer
patients (Detroit, n = 414; LA, n = 919), which was approximately 80% of those requested at each site. Tumor
blocks were not requested for all patients from these two
sites due to financial constraints. All tumor blocks were
carefully reviewed and evaluated in MFP’s pathology laboratory at University of Southern California.
We excluded 127 patients’ samples because the tumor
blocks contained only carcinoma in situ (n = 56) or no
tumor tissue (n = 46); had insufficient tissue for assay
(n = 3); contained only hematoxylin-and-eosin-stained
tissue (n = 8); or had other problems that made the
evaluation difficult (n = 14). The expression of ER was
determined for the remaining 1,206 samples (Detroit,
n = 367; LA, n = 839).
The expression of ER was determined using previously
published IHC methods [13]. In brief, the ER IHC method
involved heat-induced antigen retrieval (pH 6.0) with a sodium citrate buffer, the use of a commercially available
anti-ER mouse monoclonal primary antibody (1D5, 1:50
dilution; Zymed, Inc., South San Francisco, CA, USA), a
biotinylated secondary rabbit anti-mouse antibody (Zymed,
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We did not assay Ki67 so excluded that part of the
equation. The variable ER10 was generated by dividing
the ER H-score by 30; PR10 was calculated as the percentage of tumor cell nuclei positively stained for PR divided by 10; HER2 was scored as 0 if negative and as 1 if
positive. The combined score is referred to as the ER/
PR/HER2 score in this article.

A 600

20
-39

IHC4 ¼ 94:7  ½–0:100 ER10 –0:079 PR10 þ 0:586 HER2
þ0:240 lnð1 þ 10 Ki67Þ

Analyses were conducted using deaths due to breast
cancer (International Classification of Diseases codes
ICD9-174, ICD10-C50) as endpoints. Follow-up in days
began with breast cancer diagnosis and ended with the
woman’s death due to breast cancer (n = 272), her death
due to another cause (n = 63), or the end of the followup period (n = 869). We did not include deaths due to

<1

IHC for PR and HER2 was also conducted in the same
central pathology laboratory using methods that have
been described previously [16]. PR expression was quantified as the percentage of tumor cell nuclei positively
stained for PR. For HER2, no (0) or weak (1+) membrane
protein immunostaining was considered low HER2 expression (HER2–); and moderate (2+) or strong membrane protein immunostaining (3+) was considered HER2
overexpression (HER2+) based on previously validated results from the same pathology laboratory comparing IHC
with HER2 gene amplification measured by fluorescent
in situ hybridization methods [17].
A combined score of the ER H-score with the percentage of tumor cell nuclei positively stained for PR and
HER2 positivity was generated according to Cuzick’s
IHC4 equation [11]:

Statistical analysis

<1

þð% of positively stained tumor cell nuclei at
strong intensity category  3Þ

Participants were followed annually for vital status, date of
death and cause of death, using standard SEER follow-up
procedures. Data on vital status for Detroit participants
were available through 31 December 2004; patients in LA
were followed through 31 December 2007.

1-1
9

þ ð% of positively stained tumor cell
nuclei at intermediate intensity category  2Þ

Vital status follow-up

No. of women

ER H‐score ¼ ð% of positively stained tumor cell nuclei
at weak intensity category  1Þ

Epidemiology and End Results (SEER) cancer registries.
We previously reported that the agreement between the
centralized pathology laboratory classification and reported ER status in the SEER registry was substantial
(κ = 0.70) [18]. Two women were missing information
on the tumor stage and were excluded from the statistical analyses; the final sample size for this analysis
was 1,204 women (race: 681 white, 523 black; tumor
stage: 697 localized, 507 nonlocalized).

No. of women

Inc.) with horseradish peroxidase-labeled streptavidin
(Zymed, Inc.), and detection with diaminobenzidine. Immunostaining results for ER were scored semi-quantitatively
on the basis of the visually estimated percentage of positively stained tumor cell nuclei. The intensity of nuclear
staining was scored for individual tumor cell nuclei as negative (–)/no staining, staining weakly (+), staining intermediately (++), or staining strongly (+++). A minimum of 100
tumor cells were scored with the percentage of tumor cell
nuclei in each category recorded. The sum of three staining
categories equates to the overall percentage of positively
stained tumor cell nuclei. If ≥1% of tumor cell nuclei
stained positively, the tissue sample was considered ERpositive. The ER H-score was calculated as a weighted sum
of the intensity of IHC tumor cell nuclei as follows [14,15]:
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ER H-score

Tumor characteristics

The Women’s CARE Study collected tumor stage, histologic grade, hormone receptor status, and other tumor
characteristics from the Detroit and LA Surveillance

Figure 1 Frequency distribution of estrogen receptor
expression. Percentage of tumor cell nuclei positively stained for
estrogen receptor (ER) (A) and ER Histo (H)-score (B) in 1,204 white
women and black women diagnosed with invasive breast cancer.
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causes other than breast cancer as endpoints because we
assumed that the quantity of ER expression would not
be related to these deaths.
Multivariable Cox proportional hazards models were
fit to the data to estimate the hazard ratio (HR) representing the relative risk of death due to breast cancer
associated with an ER measure (percentage of tumor cell
nuclei positively stained for ER, ER H-score, or the ER/
PR/HER2 score) and the 95% confidence interval (CI)
for the HR [19]. Models were fit to all data and by race
(white, black). These models used age (in days) as the
time metric, were stratified by age in years at diagnosis,
and were adjusted for race, study site, and tumor stage
(Model 1). A second analysis included additional adjustment for histologic grade (Model 2). The participants’
frequency distributions for each of the covariates included in these models overall and by race have been described elsewhere [20]. We categorized the percentage of
tumor cell nuclei positively stained for ER as a fivecategory variable (<1%, 1 to 39%, 40 to 59%, 60 to 79%,
80 to 100%) and used previously published categories for
the ER H-score [21]. We categorized the ER/PR/HER2
score for women diagnosed with ER-negative tumor and

those with ER-positive tumor, separately. The combined
score was categorized as a three-category variable (<0,
0, >0) in women with ER-negative tumors since approximately 67% of them scored 0. The combined score was
categorized as a four-category variable according to quartile distribution of women with an ER-positive tumor. The
association between the combined score and breast
cancer-specific mortality risk was examined for women
with ER-negative tumors and those with ER-positive tumors, respectively.
Tests for trend were conducted by fitting ordinal
values corresponding to each category of the variable
(percentage of tumor cell nuclei positively stained for
ER, ER H-score, ER/PR/HER2 score) and determining
whether the coefficient (slope of the dose response) differed statistically from 0. We also obtained HRs (95%
CIs) associated with each 10% increase in tumor cell nuclei positively stained for ER and with each 20 unit increase in the ER H-score.
To test potential effect modification by race, we
constructed a likelihood ratio test comparing two multivariable Cox proportional hazards models (likelihood
ratio test for heterogeneity of HRs for dichotomous

Table 1 Descriptive statistics for the measures of estrogen receptor expression by follow-up outcome
Overall

Overall

n = 1,204
a

ER-positive (%)

58.0

Follow-up outcome
Died from
breast cancer

Died from
other causes

Alive at the end
of follow-up

n = 272

n = 63

n = 869

b

42.5

b

67.0

PF-test

61.8b

a

Among women with ER-positive tumor
% of tumor cell nuclei positively stained for ER

64.7 (25.5)

62.2 (27.0)

65.6 (24.5)

65.1 (25.2)

0.53

ER H-scorec

100.8 (53.0)

93.0 (52.9)

104.5 (54.6)

102.2 (52.9)

0.22

ER/PR/HER2 scored

–64.8 (40.6)

–49.9 (43.5)

–65.7 (34.7)

–67.9 (39.8)

<0.0001

n = 681

n = 131

n = 24

n = 526

62.5b

47.2b

78.6b

65.8b

White women
ER-positivea (%)
a

Among women with ER-positive tumor
% of tumor cell nuclei positively stained for ER

64.6 (25.9)

58.0 (27.4)

74.4 (18.1)

65.2 (25.7)

0.03

ER H-scorec

100.7 (53.2)

82.3 (48.8)

122.1 (44.9)

102.8 (53.7)

0.004

ER/PR/HER2 scored

–67.6 (39.7)

–46.1 (44.7)

–78.8 (26.3)

–70.8 (38.2)

<0.0001

n = 523

n = 141

n = 39

n = 343

51.3b

38.0b

60.0b

55.8b

Black women
ER-positivea (%)
a

Among women with ER-positive tumor
% of tumor cell nuclei positively stained for ER

64.8 (24.9)

67.2 (25.9)

58.3 (26.9)

65.0 (24.3)

0.35

ER H-scorec

100.9 (52.8)

105.5 (55.2)

90.0 (58.4)

101.0 (51.5)

0.50

ER/PR/HER2 scored

–60.3 (41.8)

–54.3 (42.1)

–54.8 (37.4)

–62.7 (42.1)

0.35

Data presented as mean (standard deviation). ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
a
ER-positive, ≥1% positively stained tumor cell nuclei.
b
The distribution of age at diagnosis in each subgroup was adjusted according to the distribution of age at diagnosis among the 1,204 participants (35 to 39, 40
to 44, 45 to 49, 50 to 54, 55 to 59, or 60 to 64 years).
c
ER Histo (H)-score = (% of positively stained tumor cell nuclei at weak intensity category × 1) + (% of positively stained tumor cell nuclei at intermediate intensity
category × 2) + (% of positively stained tumor cell nuclei at strong intensity category × 3).
d
ER/PR/HER2 score = 94.7 × (–0.100 ER10 – 0.079 PR10 + 0.586 HER2).
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Table 2 Breast cancer-specific mortality associated with percentage of tumor cell nuclei positively stained for estrogen
receptor
% of cells staining

Number
of women

Number
of deaths

Adjusted HR (95% CI)
Model 1a

Model 2b

Overall
<1 (ER-negative)

506

157

Referent

Referent

≥1 (ER-positive)

698

115

0.53 (0.41 to 0.68)

0.64 (0.48 to 0.85)

1 to 39

117

27

0.81 (0.53 to 1.24)

0.93 (0.60 to 1.43)

40 to 59

118

18

0.55 (0.34 to 0.91)

0.66 (0.39 to 1.12)

60 to 79

193

31

0.50 (0.33 to 0.74)

0.57 (0.38 to 0.88)

80 to 100

270

39

0.43 (0.30 to 0.62)

0.52 (0.35 to 0.78)

Trend

Ptrend <0.0001

Ptrend = 0.0003

Trend in women with ER-positive tumors only

Ptrend = 0.004

Ptrend = 0.006

Per 10% increase

0.92 (0.89 to 0.95)

0.94 (0.91 to 0.97)

Per 10% increase in women with ER-positive tumors only

0.91 (0.84 to 0.99)

0.91 (0.84 to 0.99)

White women
<1 (ER-negative)

251

69

Referent

Referent

≥1 (ER-positive)

430

62

0.42 (0.29 to 0.61)

0.56 (0.36 to 0.87)

1 to 39

75

18

0.81 (0.46 to 1.43)

1.04 (0.57 to 1.91)

40 to 59

66

10

0.46 (0.22 to 0.94)

0.65 (0.30 to 1.43)

60 to 79

123

17

0.37 (0.21 to 0.66)

0.47 (0.25 to 0.86)

80 to 100

166

17

0.28 (0.16 to 0.50)

0.39 (0.21 to 0.73)

Trend

Ptrend <0.0001

Ptrend = 0.0004

Trend in women with ER-positive tumors only

Ptrend = 0.001

Ptrend = 0.002

Per 10% increase

0.88 (0.84 to 0.93)

0.91 (0.86 to 0.96)

Per 10% increase in women with ER-positive tumors only

0.85 (0.76 to 0.96)

0.86 (0.76 to 0.96)

Black women
<1 (ER-negative)

255

88

Referent

Referent

≥1 (ER-positive)

268

53

0.56 (0.39 to 0.81)

0.62 (0.42 to 0.94)

1 to 39

42

9

0.56 (0.28 to 1.15)

0.63 (0.30 to 1.29)

40 to 59

52

8

0.50 (0.24 to 1.06)

0.55 (0.25 to 1.21)

60 to 79

70

14

0.60 (0.33 to 1.08)

0.65 (0.35 to 1.21)

80 to 100

104

22

0.56 (0.34 to 0.93)

0.64 (0.37 to 1.10)

Trend

Ptrend = 0.007

Ptrend = 0.06

Trend in women with ER-positive tumors only

Ptrend = 0.54

Ptrend = 0.67

Per 10% increase

0.94 (0.90 to 0.98)

0.95 (0.91 to 1.00)

Per 10% increase in women with ER-positive tumors only

0.98 (0.85 to 1.12)

1.00 (0.87 to 1.14)

ER-positive versus ER-negative

Phomogeneity = 0.56

Phomogeneity = 0.55

Trend

Phomogeneity = 0.13

Phomogeneity = 0.12

Trend in women with ER-positive tumors only

Phomogeneity = 0.05

Phomogeneity = 0.02

Per 10% increase

Phomogeneity = 0.16

Phomogeneity = 0.15

Per 10% increase in women with ER-positive tumors only

Phomogeneity = 0.06

Phomogeneity = 0.02

Homogeneity between white women and black women

CI, confidence interval; ER, estrogen receptor; HR, hazard ratio.
a
Multivariable Cox proportional hazards regression models using age (in days) as the time metric stratified by age (in years) and adjusted for race (white, black),
study site (Detroit, Los Angeles), tumor stage (localized, non-localized).
b
Additionally adjusted for histologic grade (low, intermediate, high).
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A
HR (95% CI)

variable (ER-positive vs. ER-negative), HRs for trends,
HRs for per 10% increase in tumor cell nuclei positively
stained for ER, or HRs for per 20 unit increase in ER
H-score, with 1 degree of freedom) [22].
All reported P values are two-sided. All statistical analyses were performed using SAS version 9.2 software
(SAS Institute, Cary, NC, USA).
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The frequency distributions of the percentage of tumor
cell nuclei positively stained for ER and ER H-score are
shown in Figure 1A and B, respectively.
Of 1,204 women, 58% were diagnosed with ER-positive
(≥1% positively stained tumor cell nuclei) breast cancer
(Table 1). The percentage of women with ER-positive
breast cancer was lower among women who died from
breast cancer (42.5%) than among women who died from
other causes (67.0%) or among women who were alive at
the end of the follow-up period (61.8%). The differences
across these three outcome groups were also observed
by race. Further, black women were less likely to have
ER-positive disease than white women (overall: 51.3%
vs. 62.5%).
Among all women with ER-positive breast cancer, the
mean percentage of tumor cell nuclei positively stained
for ER was 64.7%, the mean ER H-score was 100.8, and
the mean ER/PR/HER2 score was –64.8. The percentage
of tumor cell nuclei positively stained for ER and the ER
H-score were, on average, lower among those who died
from breast cancer than among those in other outcome
groups in white women (both PF-test ≤0.03), but not in
black women (both PF-test ≥0.35). Women who died
from breast cancer had a higher ER/PR/HER2 score than
those in the other outcome groups in white women
(mean ER/PR/HER2 score: –46.1, –78.8, –70.8 for three
outcome groups, respectively; PF-test <0.0001), but not in
black women (mean ER/PR/HER2 score: –54.3, –54.8, –
62.7 for three outcome groups, respectively; PF-test = 0.35).
Percentage of tumor cell nuclei positively stained for ER
and breast cancer-specific mortality risk

After controlling for age at diagnosis, race, study site,
tumor stage, and histologic grade, we found that ERpositivity was associated with reduced risk of breast
cancer-specific mortality (Table 2, HR = 0.64, 95% CI =
0.48 to 0.85). Further, the percentage of tumor cell nuclei positively stained for ER was inversely associated
with breast cancer-specific mortality risk (Ptrend = 0.0003,
Figure 2A). Risk estimates for breast cancer-specific
mortality decreased 6% (95% CI = 3 to 9%) for each 10%
increase in the percentage of tumor cell nuclei positively
stained for ER.

B 2.5
HR (95% CI)

Descriptive characteristics of ER expression overall and by
follow-up outcome

P trend=0.0004

2
1.5
1
0.5
0
<1 (ER-)

1-39

40-59

60-79

80-100

Percentage of tumor cell nuclei positively stained for ER in white women
P trend=0.06

C 1.4
1.2

HR (95% CI)

Results

1
0.8
0.6
0.4
0.2
0
<1 (ER-)

1-39

40-59

60-79

80-100

Percentage of tumor cell nuclei positively stained for ER in black women

Figure 2 Percentage of tumor cell nuclei positively stained for
estrogen receptor and breast cancer-specific mortality risk.
Adjusted hazard ratio (HR) estimates (95% confidence intervals (CIs))
of breast cancer-specific mortality associated with the percentage of
tumor cell nuclei positively stained for estrogen receptor (ER) in all
women (A), in white women (B), and in black women (C) with
invasive breast cancer.

Analyses by race showed that ER-positivity was associated with reduced risk of breast cancer-specific mortality
in whites and blacks (test for homogeneity of HRs for ERpositive vs. ER-negative from Model 2: P = 0.55). However,
the statistically significant inverse association between the
percentage of tumor cell nuclei positively stained for ER
and breast cancer-specific mortality risk was observed in
white women (Ptrend = 0.0004; Figure 2B), but not in black
women (Ptrend = 0.06; Figure 2C). The trends in risk with
increasing percentages of tumor cell nuclei positively
stained for ER for whites and blacks did not differ statistically when both ER-positive and ER-negative women
were studied (test for homogeneity of trends from
Model 2: P = 0.12 for trends using the categorical variable representation and P = 0.15 for trends representing
each 10% increase in tumor cell nuclei positively stained
for ER), but were statistically different in the analyses
restricted to women with ER-positive breast cancer (test
for homogeneity of trends between white women and
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Table 3 Breast cancer-specific mortality associated with the estrogen receptor Histo-score
ER H-scorea

Number
of women

Number
of deaths

Adjusted HR (95% CI)
Model 1b

Model 2c

Overall
<1 (ER-negative)

506

157

Referent

Referent

1 to 50

173

34

0.70 (0.48 to 1.03)

0.81 (0.54 to 1.21)

51 to 100

173

31

0.58 (0.39 to 0.87)

0.68 (0.45 to 1.03)

101 to 150

226

33

0.45 (0.31 to 0.67)

0.53 (0.35 to 0.81)

151 to 225

126

17

0.39 (0.23 to 0.65)

0.48 (0.28 to 0.84)

Trend

Ptrend <0.0001

Ptrend = 0.0004

Trend in women with ER-positive tumors only

Ptrend = 0.008

Ptrend = 0.02

Per 20 unit increase

0.90 (0.86 to 0.94)

0.92 (0.88 to 0.97)

Per 20 unit increase in women with ER-positive tumors only

0.90 (0.83 to 0.98)

0.90 (0.84 to 0.99)

White women
<1 (ER-negative)

251

69

Referent

Referent

1 to 50

107

22

0.66 (0.39 to 1.11)

0.85 (0.48 to 1.52)

51 to 100

104

17

0.46 (0.26 to 0.82)

0.59 (0.32 to 1.09)

101 to 150

141

18

0.34 (0.19 to 0.58)

0.45 (0.24 to 0.83)

151 to 225

78

5

0.20 (0.08 to 0.52)

0.29 (0.11 to 0.76)

Trend

Ptrend <0.0001

Ptrend = 0.0006

Trend in women with ER-positive tumors only

Ptrend = 0.008

Ptrend = 0.01

Per 20 unit increase

0.69 (0.59 to 0.79)

0.75 (0.64 to 0.88)

Per 20 unit increase in women with ER-positive tumors only

0.66 (0.49 to 0.90)

0.68 (0.50 to 0.92)

Black women
<1 (ER-negative)

255

88

Referent

Referent

1 to 50

66

12

0.51 (0.27 to 0.94)

0.56 (0.30 to 1.06)

51 to 100

69

14

0.66 (0.36 to 1.19)

0.72 (0.39 to 1.35)

101 to 150

85

15

0.55 (0.31 to 0.99)

0.61 (0.33 to 1.11)

151 to 225

48

12

0.54 (0.28 to 1.05)

0.64 (0.32 to 1.28)

Trend

Ptrend = 0.008

Ptrend = 0.07

Trend in women with ER-positive tumors only

Ptrend = 0.41

Ptrend = 0.59

Per 20 unit increase

0.93 (0.88 to 0.98)

0.95 (0.89 to 1.01)

Per 20 unit increase in women with ER-positive tumors only

0.96 (0.85 to 1.09)

0.97 (0.86 to 1.10)

Trend

Phomogeneity = 0.10

Phomogeneity = 0.09

Trend in women with ER-positive tumors only

Phomogeneity = 0.05

Phomogeneity = 0.02

Per 20 unit increase

Phomogeneity = 0.08

Phomogeneity = 0.08

Per 20 unit increase in women with ER-positive tumors only

Phomogeneity = 0.05

Phomogeneity = 0.02

Homogeneity between white women and black women

CI, confidence interval; ER, estrogen receptor; HR, hazard ratio.
a
ER Histo-score = (% of cells stained at weak intensity category × 1) + (% of cells stained at intermediate intensity category × 2) + (% of cells stained at strong
intensity category × 3).
b
Multivariable Cox proportional hazards regression models using age (in days) as the time metric stratified by age (in years) and adjusted for race (white, black),
study site (Detroit, Los Angeles), tumor stage (localized, non-localized).
c
Additionally adjusted for histologic grade (low, intermediate, high).

black women from Model 2: P = 0.02 for both trends
using the categorical variable representation and trends
representing each 10% increase in tumor cell nuclei
positively stained for ER).

Estrogen receptor Histo-score and breast cancer-specific
mortality risk

After controlling for age at diagnosis, race, study site,
tumor stage, and histologic grade, we found that ER H-
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scores were inversely associated with breast cancerspecific mortality risk (Table 3, Ptrend = 0.0004; Figure 3A).
Risk estimates for breast cancer-specific mortality decreased 8% (95% CI = 3 to 12%) for each 20 unit increase
in ER H-score.
Analyses by race showed that the statistically significant
inverse association for white women (Ptrend = 0.0006;
Figure 3B), but not for black women (Ptrend = 0.07; Figure 3C).
The difference between whites and blacks was not statistically significant when ER-positive and ER-negative women
were included (test for homogeneity of trends from Model
2: P = 0.09 for trends using the categorical variable representation and P = 0.08 for trends representing each 20 unit
increase in ER H-score), but it was statistically significant
in analyses restricted to women with ER-positive breast
cancer (test for homogeneity of trends between white
women and black women from Model 2: P = 0.02 for both
trends using categorical variable representation and the
trends representing each 20 unit increase in ER H-score).
ER/PR/HER2 score and breast cancer-specific mortality risk

After controlling for age at diagnosis, race, study site,
tumor stage, and histologic grade, no statistically signi-

HR (95% CI)

A

P trend =0.0004
1.4
1.2
1
0.8
0.6
0.4
0.2
0
<1 (ER-)

1-50

51-100

101-150

151-225

ER H-score in all women

HR (95% CI)

B

P trend =0.0006
2
1.5
1
0.5
0
<1 (ER-)

1-50

51-100

101-150

151-225

ER H-score in white women

HR (95% CI)

C

P trend =0.07
1.5
1
0.5
0
<1 (ER-)

1-50

51-100

101-150

151-225

ER H-score in black women

Figure 3 Estrogen receptor Histo-score and breast cancerspecific mortality risk. Adjusted hazard ratio (HR) estimates (95%
confidence intervals (CIs)) of breast cancer-specific mortality
associated with the estrogen receptor (ER) Histo (H)-score in all
women (A), in white women (B), and in black women (C) with
invasive breast cancer.

ficant association between the ER/PR/HER2 score and
breast cancer-specific mortality risk was observed in women with ER-negative breast cancer (Table 4). However,
in women with ER-positive tumors, the ER/PR/HER2
score was positively associated with breast cancer-specific
mortality risk (Ptrend = 0.001; Figure 4A); the HR for breast
cancer death was 2.48 (95% CI = 1.36 to 4.55) for those in
the highest quartile of the ER/PR/HER2 score compared
with those in the lowest quartile. The positive association
was observed for both white women (Ptrend = 0.01;
Figure 4B) and black women (Ptrend = 0.03; Figure 4C)
with ER-positive tumor.

Discussion
Our data showed that both the percentage of tumor cell
nuclei positively stained for ER and the ER H-score were
inversely associated with breast cancer-specific mortality
risk in all women and among those with ER-positive
breast cancer. The ER/PR/HER2 score was positively associated with breast cancer-specific mortality risk in
women with ER-positive tumors. Analyses by race revealed that ER-positivity was associated with reduced
risk of breast cancer-specific mortality in white women
and black women. Both quantitative measures for ER
alone provided additional discrimination in breast cancerspecific mortality risk for white women but not black
women with ER-positive tumors, while the ER/PR/HER2
score provided the additional discrimination for both
white women and black women with ER-positive tumors.
The association between the quantity of ER and patients’ mortality risk or survival after diagnosis has been
examined in six studies, three that used the DCC assay
[23-25] and three that used the IHC assay [21,26,27].
The largest study using the DCC assay was conducted
among 1,184 patients diagnosed with breast cancer between 1975 and 1981 who had a median follow-up of
5 years. This study found that increased concentration
of ER in tissue homogenates was associated with increased probability of breast cancer-free survival, and
this persisted after additional stratification of the data
by lymph node status, tumor stage, and menopausal
status [25].
Among the studies that used IHC, one reported that
the relative risk for all-cause mortality, adjusted for
tumor size and the percentage of nuclei stained for
proliferation-related antigen, was 0.65 (95% CI = 0.30 to
1.43) when comparing patients with >10% with those
with ≤10% of ER positively immunostained tumor cell
nuclei and was 0.44 (95% CI = 0.21 to 0.93) when comparing >30% with those with ≤30% of ER [26]. This
study was a small study with 180 primary breast cancer
patients, who had between 4 and 7 years of clinical
follow-up. Among 205 patients with ER-positive metastatic breast cancer (defined by DCC) who were followed
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Table 4 Breast cancer-specific mortality associated with the ER/PR/HER2 score
ER/PR/HER2 scorea

Number
of women

Number
of deaths

Adjusted HR (95% CI)
Model 1b

Model 2c

60

15

Referent

Referent

Women with ER-negative invasive breast cancer
Overall
<0
0

337

103

1.32 (0.76 to 2.32)

1.30 (0.74 to 2.28)

>0

109

39

1.43 (0.77 to 2.69)

1.43 (0.76 to 2.67)

Ptrend = 0.30

Ptrend = 0.29

Trend
White women
<0

35

9

Referent

Referent

0

162

46

1.20 (0.55 to 2.62)

1.09 (0.48 to 2.45)

>0

54

14

Trend

1.16 (0.46 to 2.90)

1.09 (0.43 to 2.76)

Ptrend = 0.79

Ptrend = 0.88

Black women
<0

25

6

Referent

Referent

0

175

57

1.46 (0.59 to 3.61)

1.47 (0.60 to 3.64)

>0

55

25

1.57 (0.61 to 4.06)

1.55 (0.60 to 4.03)

Ptrend = 0.42

Ptrend = 0.45

Phomogeneity = 0.36

Phomogeneity = 0.32

Trend
Homogeneity of trends between white women and black women
Women with ER-positive invasive breast cancer
Quartiles of ER/PR/HER2 scored
Overall
Q1

175

18

Referent

Referent

Q2

177

22

1.27 (0.65 to 2.45)

1.39 (0.71 to 2.70)

Q3

172

33

2.04 (1.10 to 3.81)

2.00 (1.07 to 3.76)

Q4

174

42

Trend

2.71 (1.48 to 4.95)

2.48 (1.36 to 4.55)

Ptrend = 0.0002

Ptrend = 0.001

White women
Q1

118

9

Referent

Referent

Q2

105

10

1.41 (0.53 to 3.74)

1.37 (0.52 to 3.62)

Q3

113

20

2.03 (0.84 to 4.92)

1.98 (0.82 to 4.78)

Q4

94

23

Trend

2.77 (1.19 to 6.45)

2.62 (1.12 to 6.11)

Ptrend = 0.01

Ptrend = 0.01

Black women
Q1

57

9

Referent

Referent

Q2

72

12

1.32 (0.50 to 3.51)

1.60 (0.58 to 4.45)

Q3

59

13

2.34 (0.85 to 6.42)

2.34 (0.83 to 6.55)

Q4

80

19

Trend
Homogeneity of trends between white women and black women

3.43 (1.33 to 8.84)

2.88 (1.08 to 7.67)

Ptrend = 0.006

Ptrend = 0.03

Phomogeneity = 0.56

Phomogeneity = 0.32

CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor.
a
ER/PR/HER2 score = 94.7 × (–0.100 ER10 – 0.079 PR10 + 0.586 HER2); the range of ER/PR/HER2 scores was –71.07 to 55.49 in women with ER-negative tumor and –141.10
to 53.92 in women with ER-positive tumor.
b
Multivariable Cox proportional hazards regression models using age (in days) as the time metric stratified by age (in years) and adjusted for race (white, black),
study site (Detroit, Los Angeles), tumor stage (localized, non-localized).
c
Additionally adjusted for histologic grade (low, intermediate, high); low and intermediate were combined into a single category in analyses for women with ER-negative
tumors due to a small number of women with a low grade.
d
Quartiles of ER/PR/HER2 scores in all women with ER-positive tumors were Q1 (–141.10 to –97.33), Q2 (–97.32 to –68.98), Q3 (–68.97 to –36.66), and Q4 (–36.65 to 53.92).
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Ptrend =0.001

HR (95% CI)

5
4
3
2
1
0
Q1

Q2

Q3

Q4

Quartiles of ER/PR/HER2 score in all women with ER+ tumor

B

Ptrend =0.01

HR (95% CI)

8
6
4
2
0
Q1

Q2

Q3

Q4

Quartiles of ER/PR/HER2 score in white women with ER+ tumor

HR (95% CI)

C

Ptrend =0.03
9
8
7
6
5
4
3
2
1
0
Q1

Q2

Q3

Q4

Quartiles of ER/PR/HER2 score in black women with ER+ tumor

Figure 4 ER/PR/HER2 score and breast cancer-specific mortality
risk in women diagnosed with estrogen receptor-positive
breast cancer. Adjusted hazard ratio (HR) estimates (95%
confidence intervals (CIs)) of breast cancer-specific mortality
associated with the estrogen receptor/progesterone receptor/
human epidermal growth factor receptor 2 (ER/PR/HER2) score in all
women (A), in white women (B), and in black women (C) with
ER-positive invasive breast cancer.

for a median of 9 years, the percentage of ER positively
immunostained tumor cell nuclei was positively associated with the cumulative probability of survival [27].
Another study, which included 563 postmenopausal patients with stage I or stage II breast cancer, examined
the relationships of the cumulative probability of survival with H-score and with the percentage of tumor cell
nuclei positive for ER [21]. These patients all received
adjuvant tamoxifen, but no chemotherapy following surgical resection of histologically confirmed ER-positive
breast cancer. The investigators reported that the cumulative probability of survival was positively associated with
ER H-score (10-year survival: 41%, 71%, 67%, and 84% for
H-scores of >0 to 50, 51 to 100, 101 to 200, and >200, respectively), but found no association with the percentage
of tumor cells that had ER-positive nuclei (10-year survival: 65.5%, 43.4%, and 70.9% for the percentage of cells
staining for ER of >0 to <34%, 34 to 67%, and >67%, respectively). All together, the previous studies, most of
which were hospital based, provide some evidence that a
higher level of ER expression in tumor tissue is associated
with decreased mortality risk or better survival after breast

cancer diagnosis. Our study using IHC, based on a larger
population-based sample, found that the multivariableadjusted relative hazard for breast cancer-specific mortality
decreased with increasing values of the two quantitative
measures of ER alone.
The observed inverse association of breast cancerspecific mortality risk with increased quantity of ER may
be due to the positive association between ER quantity
and response to endocrine therapy [24,28]. Clinical trials
have found that higher levels of ER expression in tumors
were associated with a lower relative risk of recurrence
[29,30]. Additionally, the inverse association may be related to the biological characteristics of breast cancers.
Supporting evidence indicates that increasing recurrencefree survival is associated with higher ER expression even
in patients who did not receive any adjuvant treatment
[25]. Early studies reported an inverse association between
the proliferation rate, determined by the thymidine labeling index, and ER content [31,32]. A higher thymidine labeling index was associated with unfavorable outcomes
such as early relapse and shorter survival time [33].
It is unclear why the inverse associations between two
quantitative measures of ER alone and breast cancerspecific mortality were observed in white women but
not in black women with ER-positive breast cancer. It is
important to note that the number of black women with
ER-positive breast cancer is relatively small compared
with white women with ER-positive breast cancer in our
study sample. Further, if black women were less likely
than white women to receive optimal treatment it is
possible that we would not observe a decreasing risk of
death with the percentage of tumor cell nuclei positively
stained for ER or the ER H-score. Prior studies have suggested that black women may receive less optimal treatment than white women [34-37]. However, we were
unable to assess treatment differences because treatment
information was not collected.
Cuzick and colleagues reported that the combined score
of ER H-score with PR/HER2/Ki-67 had prognostic value
for the distant recurrence in postmenopausal women who
were diagnosed with ER-positive breast cancer [11]. Similarly, our data, using an adaptation of Cuzick’s score,
showed that the ER/PR/HER2 score had prognostic value
for breast cancer-specific mortality for both white women
and black women with ER-positive tumors. Our data
suggest that the weighted combination of ER/PR/HER2
score provides better prognostic discrimination for breast
cancer-specific mortality risk among women with ERpositive tumors than that observed for quantitative measures of ER alone. Although Cuzick and colleagues also
found that Ki-67 provided prognostic information in
addition to ER/PR/HER2 for the risk of the distance recurrence of breast cancer [11], we unfortunately did not assay
Ki-67. Therefore, it would be valuable to assess the prog-
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nostic value of Ki-67 for breast cancer-specific mortality
risk in the future studies.

Conclusions
Our data indicate that quantitative IHC measures of ER,
especially the ER/PR/HER2 score, are more precise predictors for breast cancer-specific mortality risk than a
simple determination of ER positivity.
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